Oncology

Latest News

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com

Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

By AJMC Contributor

April 23rd 2025

Even with prevention measures and timely, aggressive intervention, tumor lysis syndrome (TLS) remains life-threatening, as a case study in small cell lung cancer (SCLC) illustrates.

Diabetes monitoring | Image credit: abidika - stock.adobe.com

New-Onset Type 2 Diabetes Linked to Higher Cancer Risk

By Pearl Steinzor

April 23rd 2025

Vitamin D | Image credit: Galina Zhigalova - stock.adobe.com

Vitamin D’s Potential Role in Colorectal Cancer Prevention, Immune Health

By Pearl Steinzor

April 23rd 2025

The study highlighted symptom patterns in the short-term preceding ED visits and unplanned hospitalizations using a previously validated natural language processing a pipeline. | Image credit: Tyler Olson - stock.adobe.com

Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities

By Rose McNulty

April 22nd 2025

Patient navigation | Image credit: AON

With Thyme Care Partnership, AON Achieves $6M in Savings in EOM’s First Performance Period

By Mary Caffrey

April 22nd 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Dr Joseph Alvarnas: Innovative Therapies Can Change Oncology Care Paradigm

January 29th 2017

Dr Joseph Alvarnas: Innovative Therapies Can Change Oncology Care Paradigm

Technological advances in cancer care have changed the very process of treatment, as now oncologists can gain more insight into the most effective therapy for each individual patient, according to Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology.

This Week in Managed Care: January 27, 2017

January 27th 2017

This Week in Managed Care: January 27, 2017

This week, the top managed care stories included Aetna and Humana's merger getting blocked, the first Affordable Care Act replacement proposal was unveiled, and an analysis of regional cancer death trends.

January 27th 2017

NICE Endorses Funding for Ibrutinib in Patients With CLL

Patients who have had at least 1 prior therapy or carry a 17p deletion or TP53 mutation are now eligible to be treated with ibrutinib (Imbruvica) in the United Kingdom.

Dr Carrie Stricker on Why Clinician Voices Are Needed in Health IT Development

January 27th 2017

Dr Carrie Stricker on Why Clinician Voices Are Needed in Health IT Development

The most transformative software companies are those that have seized the opportunity to incorporate clinician and patient voices into the design of their health IT tools, according to Carrie Stricker, PhD, RN, AOCN, chief clinical officer and co-founder of Carevive.

January 27th 2017

Coverage of 2016 American Society of Hematology Meeting Available From AJMC®

The American Journal of Managed CareÂ® presents its annual special issue of Evidence-Based Oncologyâ„¢ featuring full coverage of the 58th annual meeting of the American Society of Hematology. CAR T-cell treatments gained notice, as did sessions on patients’ improving quality of life and addressing the high costs of new therapies.

January 26th 2017

First Trial With Universal CAR-T Treatment in Pediatric Leukemia Reports Success

Surabhi Dangi-Garimella, PhD

“Off-the-shelf” chimeric antigen receptor (CAR)-T cells, also known as universal donor cells, were used in 2 young infants with relapsed, refractory acute lymphoblastic leukemia resulted in molecular remission in 28 days in both infants.

January 26th 2017

New Target for Treating Glioblastoma May Increase Survival Time

Researchers from the Peter O’Donnell Jr. Brain Institute and Harold C. Simmons Comprehensive Cancer Center at the University of Texas Southwestern may have found the ultimate drivers of glioblastoma cell proliferation.

January 25th 2017

Study Doubts Impact of Pre-ACA Medicaid Expansion on Access to Cancer Surgery

Surabhi Dangi-Garimella, PhD

Expansion of Medicaid coverage prior to the authorization of the Affordable Care Act (ACA) in 2010 reduced the uninsured rate in New York State, but did not improve access to cancer surgery.

January 25th 2017

Innovative Approach to Precision Trial Design: NCI-MATCH and Beat AML

Surabhi Dangi-Garimella, PhD

At the 58th annual meeting of the 58th American Society of Hematology, representatives from 2 national clinical trials, Beat AML and NCI-MATCH, detailed how they were incorporating genomic profiling to assign patients to different treatment arms.

January 25th 2017

JAMA Study Discovers Regional Trends in Cancer-Related Mortality

Surabhi Dangi-Garimella, PhD

An analysis of cancer death records across the country, by researchers at the University of Washington, has identified clusters of counties that had a particularly high rate of mortality depending on the cancer type.

Pam Mangat Discusses ASCO's Plans to Address Challenges of TAPUR Trial

January 25th 2017

Pam Mangat Discusses ASCO's Plans to Address Challenges of TAPUR Trial

Researchers implementing the TAPUR trial have encountered some difficulties, particularly in filling the study cohorts, said Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology (ASCO). However, the ASCO team is dedicated to forging ahead and addressing those challenges.

January 24th 2017

Study Reveals Why Immuno-Oncology Treatments Are Effective in Only a Minority of Patients

Surabhi Dangi-Garimella, PhD

A system-wide immune response, not just a local response limited to the tumor, is what determines successful remission following cancer immunotherapy.

January 23rd 2017

Two Discoveries With Cervical Cancer: Novel Regulatory Genes and the True Mortality Rate

Surabhi Dangi-Garimella, PhD

While one study identified novel mutations and gene amplifications, the other found a wider gap in racial disparity with respect to mortality rates.

January 23rd 2017

Driving Value With Innovative Approaches to Colon Cancer Screening

Although national guidelines call for men and women at average risk for colorectal cancer (CRC) to begin screening for the disease at age 50, by some estimates, compliance is a mere 38%.

January 23rd 2017

Model to Predict Disease Complexity and Costs Associated With AHCT in Acute Leukemia

Surabhi Dangi-Garimella, PhD

Disease status, MUD/MRD donor, myeloablative conditioning regimen, GVHD prophylaxis other than tacrolimus/sirolimus, and Medicare and/or Medicaid as payer are significant predictors for cost of care in patient with acute leukemia who undergo allogenic hematopoietic cell transplant (AHCT).

January 23rd 2017

Healthcare Costs and Utilization After First-Line Therapy for Medicare DLBCL Patients

Christina Mattina

Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) who relapsed following first-line treatment had higher rates of healthcare utilization and greater costs than the patients who had not relapsed.

January 23rd 2017

American Society of Hematology's Tenets for Hematologists to Choose Wisely

Surabhi Dangi-Garimella, PhD

Initiated by the American Board of Internal Medicine, Choosing WiselyÂ® is a campaign that has seen participation by a number of different national medical organizations to promote conversations between clinicians and patients to ensure adequate, evidence-based care.

Dr Sean Khozin on FDA Initiative to Analyze Data From Real-World Pipelines

January 23rd 2017

Dr Sean Khozin on FDA Initiative to Analyze Data From Real-World Pipelines

The Information Exchange and Data Transformation initiative at the FDA uses oncology data from not only clinical trials but also electronic health records and biosensors. This patient-centered approach brings research to the real world, as many oncology patients are excluded from clinical trials, said Sean Khozin, MD, MPH, senior medical officer at the FDA.

Jonathan Hirsch Discusses Challenges in Health IT Implementation

January 21st 2017

Jonathan Hirsch Discusses Challenges in Health IT Implementation

The state of current software systems, primarily electronic medical records, is a significant barrier to implementing successful health IT tools, said Jonathan Hirsch, founder and president of Syapse. He also explained some of the solutions developed by Syapse to address these challenges, like improving the software’s integration capabilities and making it more usable for providers.

January 20th 2017

Dr Richard Pazdur Confirmed Director of FDA's Oncology Center of Excellence

Surabhi Dangi-Garimella, PhD

Outgoing FDA Commissioner Robert Califf, MD, has announced that Richard Pazdur, MD, who was serving as the interim director, will now be heading the Oncology Center of Excellence.

This Week in Managed Care: January 20, 2017

January 20th 2017

This Week in Managed Care: January 20, 2017

This week, the top managed care stories included news that Republicans will introduce legislation to replace the Affordable Care Act, a report found the abortion rate hit a historic low, and results showed Januvia is safe for the oldest patients, even if they have cardiovascular risk.

January 20th 2017

ASH "Choosing Wisely Champions" Share Their Practice-Changing Success

Surabhi Dangi-Garimella, PhD

At the 2016 annual meeting, the American Society of Hematology introduced the “Choosing Wisely Champions” to recognize the efforts of practitioners who are working to eliminate costly and potentially harmful overuse of tests and procedures.

January 20th 2017

Precision Genomic Panels a Vital Clinical Support Tool in Pediatric Brain Tumors

Surabhi Dangi-Garimella, PhD

A collaborative study has concluded that genomic assays can be successfully used to identify diagnostic, prognostic, and treatment-relevant alterations and can help guide precision treatment decisions for pediatric brain tumors.

January 18th 2017

Prior Ibrutinib Treatment Improves CAR T-Cell Expansion, Could Impact Response in CLL

Surabhi Dangi-Garimella, PhD

The improved expansion of chimeric antigen receptor (CAR) T-cells indicates a deeper clinical response.

January 18th 2017

Getting Insured Could Reduce Cancer-Related Deaths Among Minorities

Surabhi Dangi-Garimella, PhD

A new report released by the American Cancer Society indicates that while the cancer-related death rate was higher among blacks than in whites in 2014, the racial gap could reduce as minority patients increasingly gain access to insurance and subsequent healthcare.

January 18th 2017

RESONATE-2 Continues to Impress With Single-Agent Ibrutinib for CLL/SLL at 29 Months

Surabhi Dangi-Garimella, PhD

Despite the complexities associated with treating older patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), patients in the RESONATE-2 trial continue to present a favorable response to single-agent ibrutinib at a follow-up of 29 months.

January 18th 2017

Phase 3 GALLIUM Study Shows Promising Results With Obinutuzumab for Follicular Lymphoma

Christina Mattina

The results showed that obinutuzumab-based immunochemotherapy and maintenance improved progression-free survival in treatment-naÃ¯ve patients with follicular lymphoma.

January 18th 2017

Ibrutinib Prevents Cytokine-Release Syndrome After CAR T-Cell Therapy for B-Cell Neoplasms

Christina Mattina

A study in a mouse model found that mice receiving chimeric antigen receptor (CAR)-T immunotherapy plus ibrutinib demonstrated longer overall survival and reduced cytokine production than the mice not treated with ibrutinib.

Dr Stuart Goldberg Explains Differences Between COTA and Traditional Data Analysis Tools

January 18th 2017

Dr Stuart Goldberg Explains Differences Between COTA and Traditional Data Analysis Tools

Data from electronic health records aren’t always helpful for oncologists, which is why the founders of Cancer Outcomes Tracking and Analysis (COTA) developed a platform that stratifies patients by relevant characteristics, said Stuart Goldberg, MD, chief medical officer, COTA, John Theurer Cancer Center.

January 17th 2017

MYSTIC Trial, Evaluating Durvalumab as First-Line in NSCLC, Adds OS Endpoint

Surabhi Dangi-Garimella, PhD

The trial, evaluating the programmed death ligand-1 inhibitor durvalumab, alone or in combination with tremelimumab, versus platinum-based chemotherapy, has refined its endpoints to include overall survival (OS) along with progression-free survival.

...

81 82 83 84 85 86 87 88 89

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions